UPDATE -- Bionano Genomics Announces its Support for the ACMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program
Patients with genetic and genomic disorders require access to medical professionals who are qualified to analyze and treat their often extremely rare conditions. Due to shortages in medical professionals in specialty areas of clinical genomics, it can be difficult for a patient to connect with board-certified PhDs or MDs in medical genetics and genomics. The Next Generation Fellowship & Residency Training Awards Program has been helping fill that gap for the past twenty years.
“As the chief executive officer for the
The Next Generation Fellowship & Residency Training Awards Program is focused on expanding the workforce pipeline by attracting excellent physicians and PhD laboratorians to genetic and genomic medicine. Bionano’s three years of financial support in this program is expected to play a significant role in the ACMGF’s work to add more experts to the field and expand the reach of genetic and genomic medicine.
“Bionano is honored and proud to support the ACMGF and the laboratory geneticists who will be supported by these fellowships,” commented
About
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the benefits of Bionano’s support of ACMGF and its Next Generation Fellowship & Residency Awards Program, Bionano’s anticipated role in advancing ACMGF’s work and building the future of clinical genomics, and the contributions of Bionano’s support toward bringing talent to the clinical genomics field. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape, including the introduction of competitive technologies or improvements in existing technologies; failure of ACMGF or its Next Generation Fellowship & Residency Awards Program to meet expectations; changes in our strategic plans; our ability to obtain sufficient financing to fund our strategic plans; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Media Relations:
Seismic
+1 (503) 799-7520
michael@teamseismic.com
Source: Bionano Genomics